ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,473.17
-0.25%
Dow Jones
39,134.76
0.77%
US Dollar vs MXN
18.3603
-0.40%
Brent Oil
85.015
0.38%
Bitcoin
65,039.65
0.10%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) Noticias

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BBIO
FechaHoraFuenteTítuloSímboloCompañía
18/06/202406:30GlobeNewswire Inc.BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)NASDAQ:BBIOBridgeBio Pharma Inc
10/06/202406:30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
06/06/202406:30GlobeNewswire Inc.BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare ConferenceNASDAQ:BBIOBridgeBio Pharma Inc
06/06/202405:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
04/06/202406:30GlobeNewswire Inc.BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for HypochondroplasiaNASDAQ:BBIOBridgeBio Pharma Inc
03/06/202415:01GlobeNewswire Inc.BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024NASDAQ:BBIOBridgeBio Pharma Inc
29/05/202415:01GlobeNewswire Inc.Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
24/05/202406:30GlobeNewswire Inc.BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingNASDAQ:BBIOBridgeBio Pharma Inc
17/05/202415:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
14/05/202406:30GlobeNewswire Inc.BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024NASDAQ:BBIOBridgeBio Pharma Inc
13/05/202406:30GlobeNewswire Inc.BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified SensitiNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202406:30GlobeNewswire Inc.BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202406:00GlobeNewswire Inc.BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipelineNASDAQ:BBIOBridgeBio Pharma Inc
07/04/202412:15GlobeNewswire Inc.BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
06/03/202416:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
05/03/202422:53GlobeNewswire Inc.BridgeBio Pharma Announces Pricing of Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202415:17GlobeNewswire Inc.BridgeBio Pharma Announces Proposed Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202401:30GlobeNewswire Inc.BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
22/02/202415:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BBIOBridgeBio Pharma Inc
22/02/202406:30GlobeNewswire Inc.BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
15/02/202415:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
13/02/202415:05Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
07/02/202406:34GlobeNewswire Inc.BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in JapanNASDAQ:BBIOBridgeBio Pharma Inc
05/02/202406:30GlobeNewswire Inc.BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
02/02/202406:00GlobeNewswire Inc.BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 MonthsNASDAQ:BBIOBridgeBio Pharma Inc
30/01/202406:00PR Newswire (US)Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsNASDAQ:BBIOBridgeBio Pharma Inc
18/01/202406:00GlobeNewswire Inc.BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic MedicinesNASDAQ:BBIOBridgeBio Pharma Inc
10/01/202416:15GlobeNewswire Inc.BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of MedicineNASDAQ:BBIOBridgeBio Pharma Inc
05/01/202415:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BBIOBridgeBio Pharma Inc
03/01/202415:30GlobeNewswire Inc.BridgeBio Pharma to Participate in the J.P. Morgan Healthcare ConferenceNASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Su Consulta Reciente

NYSE
JPM
JP Morgan Chase
FX
EURUSD
Euro vs US Dollar
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
USOTC
ADDYY
Adidas (QX)
CCOM
US30
US 30
AMEX
XLF
Financial Select Sector
CCOM
US500
US 500
NASDAQ
NVDA
NVIDIA
FX
EURMXN
Euro vs MXN
FX
USDMXN
US Dollar vs MXN
AMEX
XLV
Health Care Select Sector
NASDAQ
GOOGL
Alphabet
NYSE
MRK
Merck
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados